Eli Lilly and Company has become a key player in the development and tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant capacity to improve glycemic control and reduce the risk of cardiovascular disease. The complex manufacturing process of tirzepatide utilizes